tbuckley/cabot-search huggingface dataset:
Transitions of care and changes in distressing pain
Authors: P. C. Trask, J. Nash, J. Teno
Journal: Journal of Clinical Oncology (2004)

8078 Background: With the implementation of prospective payment for hospitals, dying cancer patients and families are faced with one or more care transitions in the last month of life. Methods: We conducted a 22 state mortality follow back survey to examine bereaved family members' perception of the level of distressing pain at the last two sites of care. Of the 1578 interviewed, 423 (48% female, 9% African-American, avg. age 72) of their family members had cancer listed as the leading cause of death on the death certificate. These 423 cases represent 550,732 persons who died from cancer based on national weights for the year 2000. Results: More than one half of the respondents (N-216) reported that the decedent was at more than one site of care in the last month. Thirty nine percent of decedents without a transition had distressing pain (% that report that pain bothered their loved one “quite a bit” or “very much”) The table below reports the percentage of individuals who experienced distressing pain and the percentage of persons with distressing pain at the second to last place who improved with care transition. Conclusion: Distressing pain is common regardless of the setting of care. With transitions, the majority of persons did not have an improvement in level of distressing pain as reported by bereaved family members. Increased attention is needed not only on how to adequately manage pain and pain-related distress, but also how to improve pain reduction measures between health care settings in the end-of-life. No significant financial relationships to disclose.
Hepatic perivascular epithelioid cell tumor (PEComa): a case report with a review of literatures
Authors: Hyun Jin Son, Dong Wook Kang, Joo Heon Kim, Hyun Young Han, Min Koo Lee
Journal: Clinical and Molecular Hepatology (2017)

Hepatic perivascular epithelioid cell tumors (PEComas) are very rare. We report a primary hepatic PEComa with a review of the literature. A 56-year-old women presented with a nodular mass detected during the management of chronic renal failure and chronic hepatitis C. Diagnostic imaging studies suggested a nodular hepatocellular carcinoma in segment 5 of the liver. The patient underwent partial hepatectomy. A brown-colored expansile mass measuring 3.2Ã3.0 cm was relatively demarcated from the surrounding liver parenchyma. The tumor was mainly composed of epithelioid cells that were arranged in a trabecular growth pattern. Adipose tissue and thick-walled blood vessels were minimally identified. A small amount of extramedullary hematopoiesis was observed in the sinusoidal spaces between tumor cells. Tumor cells were diffusely immunoreactive for human melanoma black 45 (HMB45) and Melan A, focally immunoreactive for smooth muscle actin, but not for hepatocyte specific antigen (HSA). Keywords: Hepatic; PEComa; HMB45; Melan A
UTILITY OF CARDIAC COMPUTED TOMOGRAPHY SCANNING IN THE DIAGNOSIS AND PREOPERATIVE EVALUATION OF PATIENTS WITH INFECTIVE ENDOCARDITIS
Authors: Jason Sims, Nandan Anavekar, Krishnaswamy Chandrasekaran, James Steckelberg, Walter Wilson, Bernard Gersh, Larry Baddour, Daniel DeSimone
Journal: Journal of the American College of Cardiology (2017)
Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R
Authors: C. Marosi, M. Vedadinejad, C. Haberler, J. A. Hainfellner, K. Dieckmann, K. Rössler, M. R. Hassler
Journal: Journal of Clinical Oncology (2006)

1526 Background: Despite noticeable progress in the treatment of high-grade gliomas (HGG), most patients experience tumor recurrence after standard treatment consisting of surgery, radiotherapy and concomitant chemotherapy. Imatinib mesylate, a tyrosine kinase inhibitor of PDGFR-α, -β, c-kit, abl and arg, has been shown to produce tumor response in patients with recurrent gliomas (Raymond ProcASCO 2004, Dresemann ProcASCO 2004&amp;2005, Reardon Proc ASCO 2005). We treated 34 patients with recurrent HGGs showing immunohistochemical expression of “imatinib targets” in the tumor tissue with imatinib. Methods: 34 patients, 16 women, 18 men, aged from 27 to 72 years, in median 49 years with recurrent HGG (GBM n= 23, AA n=11) were treated with imatinib 400 mg/day as continuous daily oral dosing. MRI was performed every three months or at clinical suspicion of progression. The median interval from diagnosis to the start of imatinib was 12.6 months (range 4.3 to 143 months). Imatinib was the 2 nd line therapy in 15 patients, 3 rd line in 13 and 4 th line in 6 patients. ECOG performance score at start of imatinib was 1 in 9, 2 in 21 and 3 in 4 patients, respectively.Immunohistochemical analysis was performed on formalin fixed and paraffin embedded tumor tissue with antibodies against PDGFR-α, and -β. Results: The median treatment period with imatinib was 4 months (3 weeks to 17 months). The best response achieved was major response in 2 patients, partial remission in 6, stable disease in 12 and progressive disease in 14 patients. Eleven patients were free from tumor progression after 6 months (PFS-6 32,4%). The two patients with major response improved clinically and showed no more evidence of increased metabolism as well in MRI spectroscopy as in C 11 -methionine PET for 13 and 17 months, respectively. One of them showed widespread PDGF-R-α expression in the tumor tissue. In all patients with objective response to imatinib, a clinical benefit was noted within the first month of treatment. Conclusions: Compared to the results of Raymond et al, we observed a higher percentage of patients with progression free survival at 6 months. Detailed analysis of imatinib targets in tumor tissue of patients treated with imatinib will be helpful to explore the potential of imatinib as treatment option for patients with HGG. No significant financial relationships to disclose.
Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial.
Authors: Jonathan W. Friedberg, Julie M. Vose, Jennifer L Kelly, Faith Young, Jane Liesveld, James O. Armitage, Nicole Proia, Kim Cruttenden, John P. Leonard
Journal: Blood (2009)
A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array
Authors: P. G. Johnston, K. Mulligan, E. Kay, J. Black, S. Moore, U. Mc Dermott, R. Wilson, D. Harkin
Journal: Journal of Clinical Oncology (2006)

3519 Background: We have developed the first disease specific microarray for colorectal cancer using a transcriptome-based approach. This unique tool has been specially designed and optimised for analysis of gene expression profiles from formalin fixed paraffin embedded tissues (FFPE). To evaluate this tool we are conducting a study in patients with Dukes B (stage II) colorectal cancer (CRC) using FFPE tissues to determine a prognostic genetic signature predicting disease recurrence. Methods: The colorectal array was developed using a high-throughput transcriptome-based approach and encodes over 52,500 transcripts expressed in normal and diseased colorectal tissue. To date, tumours from 32 patients have been selected (mean FFPE tissue block age - 10.4 years) from the stage II CRC cohort of a phase III randomized trial comparing 5-FU/Leucovorin versus no adjuvant treatment (NI240). The patients were from the observation alone arm;19 of whom were disease-free for 5 years post-randomisation, while 13 suffered relapse prior to 3 years. Results: RNA was extracted from all 32 FFPE tissue samples, amplified, labelled and hybridised to the colorectal cancer disease specific array. Raw data was normalised using scalar, median-polish and z-score strategies and scalar was selected as the best strategy in relation to predictive error. Within this data set genes selected by correlation using ANOVA performed best in both KNN and support vector machine algorithms (supervised). Using this approach a gene signature containing 48 genes demonstrated 100% accuracy in the prediction of relapse in stage II CRC (p&lt;0.001). This signature was also able to separate samples at the meta-node level using unsupervised hierarchical clustering. Conclusion: We have developed the first colorectal cancer disease specific microarray and demonstrated its use using FFPE tissues. Using this approach we have derived a gene signature that predicts for a high likelihood of early relapse in stage II CRC. [Table: see text]
OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG PATIENTS WITH A HISTORY OF TRANSIENT ISCHEMIC ATTACK OR CEREBROVASCULAR ACCIDENT: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM
Authors: Devraj Sukul, Milan Seth, David Wohns, Simon Dixon, Nicklaus Slocum, Hitinder Gurm
Journal: Journal of the American College of Cardiology (2017)
Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study
Authors: F. Pasini, G. de Manzoni, L. Stievano, A. Grandinetti, S. Maluta, C. Capirci, E. Durante, A. Bonetti, A. Zanoni, C. Cordiano
Journal: Journal of Clinical Oncology (2009)

4548 Background: The achievement of pathological complete response (pCR) seems essential to improve survival in EC. In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation. Based on these promising results, we have performed a phase II study. The primary end point was the pathological response rate, the secondary end points were survival and toxicity. Methods: 74 pts with stage II-III EC (37 adenocarcinomas) were enrolled; median age was 59 yrs (42–73). Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43,50,57 plus 5-FU 180 mg/m2 c.i. d 1–21 and 150 mg/m2 c.i. d 29–64; concurrent RT (50 Gy) started on d 29. Surgery was performed 6 to 8 weeks after completion of RT. Results: 65/74 pts (88%) completed the planned chemo-radiation, while 9 required dose modification of chemotherapy. Median follow-up of living pts was 40 mo (18–75). Pathological findings: pT0 pN0 (pCR): 35 (47%); pTrm pN0:11 (15%)[residual microfoci]; Others: 28 (38%). The overall median survival was 50 mo; median survival times of Others, pTrm, and pCR subsets were 17, 42 months and not reached, respectively (p&lt;0.001). The 3 years survival rates were 81%, 63.5% and 26% for pCR, pTrm and Othes subsets, respectively. During chemoradiation, grade 3–4 hematological toxicity occurred in 10 pts (13.5%); grade 3–4 non-hematological toxicities occurred in 22 pts (30%), mostly in the last 2 weeks. There were 3 toxic deaths (4%): one pulmonary embolism and 2 postoperative deaths. 67 pts underwent surgery, while 7 did not (4 progression, 3 refusal). Conclusions: High pCR rate (47%) and 3-yr survival rate of 81% were achieved. This weekly schedule allowed concomitant chemoradiation at cumulative doses impossible with three weeks protocols. Given the not negligible toxicity, this protocol requires management in dedicated institutions. [Table: see text] No significant financial relationships to disclose.
Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.
Authors: Allen Eng-Juh Yeoh, Shirley Kow-Yin Kham, Yi Lu, Toon-Chai Foo, Hany Ariffin, Thuan-Chong Quah
Journal: Blood (2006)
Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy
Authors: Magnus Tobiasson, Donal McLornan, Mohsen Karimi, Marios Dimitriou, Monika Jansson, Asmaa Ben Azenkoud, Martin Jädersten, Greger Lindberg, Hani Abdulkadir, Austin G. Kulasekararaj, Johanna Ungerstedt, Andreas Lennartsson, Karl Ekwall, Ghulam J Mufti, Eva Hellström-Lindberg
Journal: Blood (2015)
Multivariate analysis of prognostic factors in cancer of unknown primary (CUP) patients treated with site-specific therapy based on the 92-gene cancer classifier.
Authors: Catherine A. Schnabel, Yi Zhang, John D. Hainsworth, David R. Spigel, F Anthony Greco, Mark G. Erlander
Journal: Journal of Clinical Oncology (2013)

e15006 Background: Results from a single arm prospective study demonstrated overall survival of 12.5m in 194 patients that received first-line therapy directed by tumor classification using the 92-gene assay (JCO, 31:217-23). When the molecular assay predicted tumor types that were clinically more responsive, median survival was significantly improved when compared with predictions of more resistant tumors (13.4 v 7.6 m; p= 0.04).In this analysis, the survival benefit of assay-directed therapy was further evaluated after adjusting for pre-treatment prognostic factors. Methods: Cox proportional hazards regression was used to examine survival benefit of responsive tumor types (n=115) vs resistant tumor types (n=79) predicted by the molecular assay, after controlling for traditional prognostic factors. Results: Univariate Cox regression analysis (n=194) showed that ECOG status, responsive vs resistant tumor type, and assay probability were each significant prognostic factors. In multivariate analyses, the prognostic value of only ECOG status and the assay prediction of responsive vs resistant tumor type were maintained. Conclusions: These data demonstrate that the 92-gene assay results remained a significant independent variable affecting survival outcome in these patients after adjustment for prognostic heterogeneity, and provide further support of assay accuracy in molecular classification of CUP. Clinical trial information: NCT00737243. [Table: see text]
N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE, RACE, AND FLOW-MEDIATED DILATION: MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Sushan Yang, Shi Huang, Joseph Yeboah, Lori Daniels, Joao Lima, Joshua Beckman, John Carr, Thomas Wang, Deepak Gupta
Journal: Journal of the American College of Cardiology (2017)
Evaluation à moyen terme du traitement endoscopique des carcinomes épidermoïdes superficielles de l'oesophage. Etude rétrospective multicentrique
Authors: A Berger, G Rahmi, M Pioche, G Perrod, JM Canard, E Metivier-Cesbron, E Samaha, A Vienne, V Lepilliez, C Cellier
Journal: Endoscopy (2017)

Le traitement chirurgical des carcinomes épidermoïdes localisés de l'oesophage est associé à une morbi-mortalité significative. Pour les tumeurs superficielles, l'alternative est la résection endoscopique par mucosectomie (EMR) ou dissection sous muqueuse (ESD) qui sont les 2 principales techniques utilisées. Après résection endoscopique, il existe peu de données sur l'évolution carcinologique à long terme suivant la technique endoscopique utilisée.. L'objectif de ce travail était d'évaluer l'efficacité de la résection endoscopique et son évolution à long terme en fonction des critères de résection carcinologiques.
Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers
Authors: Carla Verri, Cristina Borzi, Todd Holscher, Matteo Dugo, Andrea Devecchi, Katherine Drake, Stefano Sestini, Paola Suatoni, Elisa Romeo, Gabriella Sozzi, Ugo Pastorino, Mattia Boeri
Journal: Journal of Thoracic Oncology (2017)

BackgroundThe issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown.MethodsTargeted next-generation sequencing was performed on 94 LDCT screening–detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed.ResultsThe mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66% and 100%, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42% to 97% (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02).ConclusionTumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.
F<scp>ifty</scp> Y<scp>ears of</scp> R<scp>esearch in</scp> ARDS.Respiratory Mechanics in Acute Respiratory Distress Syndrome
Authors: William R. Henderson, Lu Chen, Marcelo B. P. Amato, Laurent J. Brochard
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Acute respiratory distress syndrome is a multifactorial lung injury that continues to be associated with high levels of morbidity and mortality. Mechanical ventilation, although lifesaving, is associated with new iatrogenic injury. Current best practice involves the use of small Vt, low plateau and driving pressures, and high levels of positive end-expiratory pressure. Collectively, these interventions are termed "lung-protective ventilation." Recent investigations suggest that individualized measurements of pulmonary mechanical variables rather than population-based ventilation prescriptions may be used to set the ventilator with the potential to improve outcomes beyond those achieved with standard lung protective ventilation. This review outlines the measurement and application of clinically applicable pulmonary mechanical concepts, such as plateau pressures, driving pressure, transpulmonary pressures, stress index, and measurement of strain. In addition, the concept of the "baby lung" and the utility of dynamic in addition to static measures of pulmonary mechanical variables are discussed.
THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF)
Authors: Sean Chen, Anne Hellkamp, Richard Becker, Scott Berkowitz, Guenter Breithardt, Keith Fox, Werner Hacke, Jonathan Halperin, Graeme Hankey, Kenneth Mahaffey, Christopher Nessel, Jonathan Piccini, Daniel Singer, Manesh Patel
Journal: Journal of the American College of Cardiology (2017)
<i>Notes from the Field</i>: Investigation of Patients Testing Positive for Yellow Fever Viral RNA After Vaccination During a Mass Yellow Fever Vaccination Campaign — Angola, 2016
Authors: Andrew T. Boyd, Diambi Dombaxe, Rosa Moreira, M.S. Oliveira, Eusebio Manuel, Carlos Navarro Colorado, Tatiana M. Lanzieri
Journal: MMWR Morbidity and Mortality Weekly Report (2017)
ASSOCIATION BETWEEN QRS DURATION ON PREHOSPITAL ELECTROCARDIOGRAM AND EARLY OUTCOME IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Rikke Hansen, Martin Frydland, Matias G. Lindholm, Ole Moller-Helgestad, Jesper Kjaergaard, Lisette Jensen, Lene Holmvang, Hanne B. Ravn, Christian Hassager, Jacob Møller
Journal: Journal of the American College of Cardiology (2017)
THE ASSOCIATION OF CORONARY ARTERY DISEASE SEVERITY AND PRE PROCEDURAL COMPLETENESS OF REVASCLARIZATION ON MORTALITY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Guy Witberg, Ehud Regev, Shmuel Chen, Abid Assali, Issi Barbash, David Planer, Hana Vaknin Assa, Victor Guetta, Vicky Zeniou, Katia Orvin, Haim Danenberg, Amit Segev, Ran Kornowski
Journal: Journal of the American College of Cardiology (2017)
UN NUEVO HIDROGEL PARA PREVENIR EL SÍNDROME DE COAGULACIÓN, ESTUDIO EXPERIMENTAL EN RATAS Y CERDOS
Authors: V Lorenzo-Zúñiga García, R Bartolí, V Moreno De Vega Lomo, J Boix
Journal: Endoscopy (2015)

Introducción: La incidencia del daño térmico profundo de la mucosa, o síndrome de coagulación (SC), se ha incrementado en los últimos años con la difusión de las técnicas de resección endoscópica avanzada. Para prevenirlo se ha desarrollado un nuevo hidrogel (producto).
Chronic lymphocytic leukemia (CLL) coexistent with HIV: An increasing association?
Authors: J. Cole, L. Pantanowitz, D. M. Aboulafia
Journal: Journal of Clinical Oncology (2009)

7078 Background: In the era of highly active antiretroviral therapy (HAART) HIV-seropositive patients are living longer. With improvements in overall survival the frequency and pattern of malignancies seen in these patients are changing. CLL is the most common leukemia in Western countries, yet very little has been published regarding HIV coexistent with CLL. Therefore, the aim of this study was to evaluate the clinicopathological findings and outcome of HIV-associated CLL in a series of cases. Methods: Cases of HIV-associated CLL/small lymphocytic leukemia (SLL) were collected from the authors’ archives and published case reports (using PubMed search). Information regarding patient demographics (age, gender), mode of HIV acquisition, HAART use, immunosuppression (HIV Viral load [VL], CD4+ cell count), clinical presentation, pathology, and outcome were abstracted and analyzed. Results: A total of 6 patients were identified (4 personal cases, 2 published reports) with a median patient age of 60 years (range, 50–76), 5 of whom were male. Five were homosexual and 1 heterosexual. Five patients were on HAART. Immunologic parameters available for 4 patients showed a median CD4+ count of 930 cells/mm3 (range, 396–1374) and mean HIV VL of 2,103 copies/ml (range, &lt;75–5,297). Persistent lymphocytosis was noted in 5 cases and 4 patients had persistent/progressive lymphadenopathy. CLL/SLL was diagnosed by lymph node biopsy (n = 1) and/or flow cytometry (n = 5). Two patients remained well without treatment and 4 required therapy due to either hemolytic anemia, CLL- induced renal failure, pancytopenia, or hypogammaglobulinemia with recurrent infections. One individual died of renal failure and two from infectious complications. Conclusions: CLL/SLL may occur in association with HIV infection in the elderly without significant concomitant immunosuppression. CLL-related complications in our small series were frequent (67%), including mortality (50%). Additional cases of CLL/SLL are anticipated as HIV-infected patients in the HAART era are reported to be living longer. The association between HIV and CLL is deserving of further attention and we encourage clinicians to report their findings. No significant financial relationships to disclose.